Related references
Note: Only part of the references are listed.Lysosomal dysfunction in Schwann cells is involved in bortezomib-induced peripheral neurotoxicity
Zhanxun Wu et al.
ARCHIVES OF TOXICOLOGY (2023)
Involvement of the CD39/CD73/adenosine pathway in T-cell proliferation and NK cell-mediated antibody-dependent cell cytotoxicity in Sezary syndrome
Gabrielle Sonigo et al.
BLOOD (2022)
RAF1-MEK/ERK pathway-dependent ARL4C expression promotes ameloblastoma cell proliferation and osteoclast formation
Shinsuke Fujii et al.
JOURNAL OF PATHOLOGY (2022)
Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in H/NRASQ61X Mutant Rhabdomyosarcoma
Natalia Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2022)
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
Meletios A. Dimopoulos et al.
BLOOD CANCER JOURNAL (2022)
Proteasome inhibitor immunotherapy for the epithelial to mesenchymal transition: assessing the A549 lung cancer cell microenvironment and the role of M1, M2a and M2c 'hydrocortisone-polarised' macrophages
Selin Engur-Ozturk et al.
MOLECULAR BIOLOGY REPORTS (2022)
Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents
Roberta Turiello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors
Jonas Schwestermann et al.
FRONTIERS IN ONCOLOGY (2022)
CD73 in small extracellular vesicles derived from HNSCC defines tumour-associated immunosuppression mediated by macrophages in the microenvironment
Tingwei Lu et al.
JOURNAL OF EXTRACELLULAR VESICLES (2022)
A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape
Markus Kellner et al.
BIOMEDICINES (2022)
CD73 aggravates alcohol-related liver fibrosis by promoting autophagy mediated activation of hepatic stellate cells through AMPK/AKT/mTOR signaling pathway
Xue Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2022)
Extracellular vesicles derived from GMSCs stimulated with TNF-α and IFN-α promote M2 macrophage polarization via enhanced CD73 and CD5L expression
Yukari Watanabe et al.
SCIENTIFIC REPORTS (2022)
TTYH3 Modulates Bladder Cancer Proliferation and Metastasis via FGFR1/H-Ras/A-Raf/MEK/ERK Pathway
Polash Kumar Biswas et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Loss of VOPP1 Contributes to BET Inhibitor Acquired Resistance in Non-Small Cell Lung Cancer Cells
Lin Sun et al.
MOLECULAR CANCER RESEARCH (2022)
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma
Meletios Dimopoulos et al.
BLOOD (2021)
CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer
Sebastian Griesing et al.
ANTICANCER RESEARCH (2021)
Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1
Qian Wu et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Targeting adenosine and regulatory T cells in cancer immunotherapy
Alexey Churov et al.
HUMAN IMMUNOLOGY (2021)
CD73-positive extracellular vesicles promote glioblastoma immunosuppression by inhibiting T-cell clonal expansion
Ming Wang et al.
CELL DEATH & DISEASE (2021)
Proteasome inhibition by bortezomib parallels a reduction in head and neck cancer cells growth, and an increase in tumor-infiltrating immune cells
Monica Benvenuto et al.
SCIENTIFIC REPORTS (2021)
Increased Extracellular Adenosine in Radiotherapy-Resistant Breast Cancer Cells Enhances Tumor Progression through A2AR-Akt-β-Catenin Signaling
Hana Jin et al.
CANCERS (2021)
A Novel CD73 Inhibitor SHRI70008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-I Blockade in a Mouse Model of Breast Cancer
Suxing Liu et al.
ONCOTARGETS AND THERAPY (2021)
Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter
Yu-Nan Tian et al.
CELL DEATH & DISEASE (2020)
Cancer-associated fibroblasts enhance the chemoresistance of CD73(+) hepatocellular carcinoma cancer cells via HGF-Met-ERK1/2 pathway
Hao Peng et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
Fazal Shirazi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Fibroblast growth factor 2 upregulates ecto-5′-nucleotidase and adenosine deaminase via MAPK pathways in cultured rat spinal cord astrocytes
Ryota Eguchi et al.
PURINERGIC SIGNALLING (2020)
Targeting the CD73-adenosine axis in immuno-oncology
David Allard et al.
IMMUNOLOGY LETTERS (2019)
Therapeutic potency of pharmacological adenosine receptors agonist/antagonist on cancer cell apoptosis in tumor microenvironment, current status, and perspectives
Anvar Soleimani et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
A Novel Specific Anti-CD73 Antibody Inhibits Triple-Negative Breast Cancer Cell Motility by Regulating Autophagy
Zheng Qiao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study
Noemi Horvath et al.
LEUKEMIA & LYMPHOMA (2019)
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine
Chang-Qing Tian et al.
CELL DEATH & DISEASE (2019)
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
L. Buisseret et al.
ANNALS OF ONCOLOGY (2018)
Proteasome inhibitors: structure and function
Ana T. Nunes et al.
SEMINARS IN ONCOLOGY (2017)
CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF--mTOR-HIF-1 signaling in patients with non-small cell lung cancer
Jieyao Li et al.
ONCOIMMUNOLOGY (2017)
Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases
Dipti Vijayan et al.
ONCOIMMUNOLOGY (2017)
Leucovorin Enhances the Anticancer Effect of Bortezomib in Colorectal Cancer Cells
Shu Wang et al.
SCIENTIFIC REPORTS (2017)
Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study
Jennifer Brown et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy
Martin Turcotte et al.
CANCER RESEARCH (2017)
Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
Silvia Xargay-Torrent et al.
CLINICAL CANCER RESEARCH (2013)
Ensemble of Gene Signatures Identifies Novel Biomarkers in Colorectal Cancer Activated through PPAR gamma and TNF alpha Signaling
Stefano Maria Pagnotta et al.
PLOS ONE (2013)
Activated hepatic stellate cells upregulate transcription of ecto-5′-nucleotidase/CD73 via specific SP1 and SMAD promoter elements
Michel Fausther et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2012)
Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression
Fanny Chalmin et al.
IMMUNITY (2012)
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells
Sudharsan Periyasamy-Thandavan et al.
AUTOPHAGY (2010)
Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study
Ioannis Psallidas et al.
MOLECULAR CANCER (2010)
Identification and Functional Characterization of ERK/MAPK Phosphorylation Sites in the Runx2 Transcription Factor
Chunxi Ge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Stimulation by vasopressin of ERK phosphorylation and vector-driven water flux in astrocytes is transactivation-dependent
Ting Du et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2008)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
The proteasome inhibitor, PS-341, causes cytokeratin aggresome formation
F Bardag-Gorce et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2004)
Wnt and β-catenin signaling target the expression of ecto-5′-nucleotidase and increase extracellular adenosine generation
J Spychala et al.
EXPERIMENTAL CELL RESEARCH (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Share Paper
